Female or male patients, aged at least 18 years (no upper limit of age)
ECOG PS 0 or 1
Life expectancy of at least 3 months
Patients with histologically or cytologically documented metastatic or refractory/recurrent HPV-16 + cancer. Phase Ib: cervical, vulvar, vaginal, penile,    
anal, and oropharyngeal squamous cell carcinoma of head and neck. Phase II part: an expansion cohort of oropharyngeal SCCHN will be included
Disease MUST not be amenable to curative surgery resection or curative radiotherapy with documented disease progression
Prior therapy: Patients MAY have received up to 2 prior lines of systemic chemotherapy for the management of metastatic or recurrent disease; for SCCHN, patients MUST have  
previously been exposed to platinum-based therapy, either as part of definitive chemo-radiation OR as first line systemic treatment for metastatic disease which may  
include cetuximab. Patients with recurrence/progression within 6 months of prior multimodal therapy using platinum-based therapy are eligible. Patients with cervical  
cancer may have undergone surgery and/or received definitive radiation or chemo-radiation therapy for localized disease.                                        
Availability of tumor tissue from biopsy
At least one measurable lesion by CT scan according to RECIST 1.1.
Adequate hematological, hepatic and renal function
Negative blood pregnancy test at screening for women of childbearing potential
Highly effective contraception for both male and female patients if the risk of conception exists during the study period and for 3 months after the last study treatment administration
